Australia markets closed
  • ALL ORDS

    7,670.90
    +12.00 (+0.16%)
     
  • ASX 200

    7,394.40
    +8.00 (+0.11%)
     
  • AUD/USD

    0.7368
    -0.0018 (-0.24%)
     
  • OIL

    72.17
    +0.26 (+0.36%)
     
  • GOLD

    1,802.10
    -3.30 (-0.18%)
     
  • BTC-AUD

    46,347.60
    +47.75 (+0.10%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • AUD/EUR

    0.6255
    -0.0015 (-0.24%)
     
  • AUD/NZD

    1.0560
    -0.0027 (-0.25%)
     
  • NZX 50

    12,736.32
    +15.48 (+0.12%)
     
  • NASDAQ

    15,111.79
    +171.63 (+1.15%)
     
  • FTSE

    7,027.58
    +59.28 (+0.85%)
     
  • Dow Jones

    35,061.55
    +238.20 (+0.68%)
     
  • DAX

    15,669.29
    +154.75 (+1.00%)
     
  • Hang Seng

    27,321.98
    -401.86 (-1.45%)
     
  • NIKKEI 225

    27,548.00
    +159.80 (+0.58%)
     

Global Axial Spondyloarthritis (axSpA) Market Spotlight 2021-2031: Marketed & Pipeline Dugs, Clinical Trials, Regulatory Events, Probability of Success, Disease Prevalence, Revenues - ResearchAndMarkets.com

·3-min read

DUBLIN, Jun 14, 2021--(BUSINESS WIRE)--The "Market Spotlight: Axial Spondyloarthritis (axSpA)" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

The publisher estimates that in 2018, there were 5.9 million prevalent cases of ankylosing spondylitis in adults aged 20 years and older worldwide, and forecasts that number to increase to 6.4 million prevalent cases by 2027.

The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, interleukin 17, IL-17 receptor, and JAK/STAT. These are commonly administered via the subcutaneous route, with the remainder being intravenous, oral, and percutaneous catheter/injection formulations.

The greatest proportion of industry-sponsored drugs in active clinical development for axSpA are in the NDA/BLA phase. Therapies in development for axSpA focus on targets such as JAK/STAT, interleukin 17, and granulocyte-macrophage colonystimulating factor. These drugs are administered via the oral, intravenous, subcutaneous, and topical routes.

High-impact upcoming events in the axSpA space comprise topline Phase III trial results for bimekizumab, Cosentyx, and Rinvoq; and expected PDUFA dates for Rinvoq and Xeljanz/Xeljanz XR.

The overall likelihood of approval of a Phase I arthritis asset is 8.4%, and the average probability a drug advances from Phase III is 80%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 9.2 years in the overall autoimmune/immunology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for ankylosing spondylitis have been in the late phases of development, with 82% of trials in Phase III-IV, and only 18% in Phase I-II.

Germany has a significant lead in the number of ankylosing spondylitis clinical trials globally, while South Korea has the top spot in Asia.

Clinical trial activity in the ankylosing spondylitis space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for ankylosing spondylitis, with 28 trials.

Pfizer leads industry sponsors with the highest overall number of clinical trials for ankylosing spondylitis, followed by AbbVie

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Definition

  • Patient segmentation

  • Symptoms

  • Risk factors

  • Diagnosis

TREATMENT

NSAIDs

DMARDs

  • Steroids

  • Surgery

EPIDEMIOLOGY

  • Epidemiology of axial spondyloarthritis

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Xeljanz/Xeljanz XR for Axial Spondyloarthritis (November 6, 2020)

  • Cosentyx for Axial Spondyloarthritis (November 12, 2019)

  • Rinvoq for Axial Spondyloarthritis (November 12, 2019)

  • Taltz for Axial Spondyloarthritis (November 12, 2019)

  • Inflectra for Axial Spondyloarthritis (September 19, 2019)

  • Cosentyx for Axial Spondyloarthritis (September 17, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Sandoz Confirms Launch Of Humira Rival In Canada

  • Celltrion Wins Global First Approval For High-Concentration Humira Biosimilar

  • Henlius Gets Green Light For Adalimumab In China

  • AbbVie's Rinvoq Advances Along Aggressive Growth Plan

  • Extra Indications Approved For Celltrion's Remsima SC

  • FDA Approves Mylan's Humira Biosimilar

  • Japan Approves First Humira Biosimilar

  • New Indications For Novartis, Ultragenyx

  • Mylan And Lupin Prepare To Launch EU Etanercept

  • Mylan And Lupin Get EU Etanercept Nod

  • Celltrion Eyes 'Competitive Edge' With Adalimumab Filing

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/i7ele0

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005324/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting